{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:17:59Z","timestamp":1793276279353,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.berh.2021.101719","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T18:53:49Z","timestamp":1635447229000},"page":"101719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Treatment advances in gout"],"prefix":"10.1016","volume":"35","author":[{"given":"Lisa K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Farquhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2021.101719_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X211028007","article-title":"Inequities in people with gout: a focus on M\u0101ori (Indigenous People) of Aotearoa New Zealand","volume":"13","author":"Te Karu","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"6","key":"10.1016\/j.berh.2021.101719_bib2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.semnephrol.2020.12.001","article-title":"Pathophysiology of gout","volume":"40","author":"Narang","year":"2020","journal-title":"Semin Nephrol"},{"issue":"6","key":"10.1016\/j.berh.2021.101719_bib3","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"American College of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.berh.2021.101719_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036748","article-title":"Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis","volume":"10","author":"Li","year":"2020","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.berh.2021.101719_bib5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.24402","article-title":"Efficacy and safety of pharmacologic interventions in patients experiencing a gout flare: a systematic review and network meta-analysis","volume":"73","author":"Zeng","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2021.101719_bib6","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rhem Dis"},{"key":"10.1016\/j.berh.2021.101719_bib7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2021.101719_bib8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/key402","article-title":"Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial","volume":"58","author":"Janssen","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2021.101719_bib9","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.41699","article-title":"A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares","volume":"73","author":"Saag","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2021.101719_bib10","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.berh.2021.101719_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13075-018-1664-2","article-title":"NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis","volume":"20","author":"Marchetti","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.berh.2021.101719_bib12","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2021.101719_bib13","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","article-title":"Patient and provider barriers to effective management of gout in general practice: a qualitative study","volume":"71","author":"Spencer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101719_bib14","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricaemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2021.101719_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A\u00a0retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricaemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.berh.2021.101719_bib16","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2021.101719_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleos Nucleot Nucleic Acids"},{"key":"10.1016\/j.berh.2021.101719_bib18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101719_bib19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-021-02416-y","article-title":"Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review","volume":"23","author":"Pisaniello","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2021.101719_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2021.101719_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the American College of physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.berh.2021.101719_bib22","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10264","key":"10.1016\/j.berh.2021.101719_bib23","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.berh.2021.101719_bib24","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/art.40583","article-title":"New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and drug administration public safety aler","volume":"70","author":"Choi","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2021.101719_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.41638","article-title":"Reassessing the cardiovascular safety of febuxostat: implications of the febuxostat versus allopurinol streamlined trial","volume":"73","author":"Choi","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101719_bib26","article-title":"The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): a network meta-analysis of randomized trials","author":"Zhang","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.berh.2021.101719_bib27","doi-asserted-by":"crossref","first-page":"698437","DOI":"10.3389\/fmed.2021.698437","article-title":"Cardiovascular safety of febuxostat and allopurinol in hyperuricemic patients with or without gout: a network meta-analysis","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Med"},{"issue":"7","key":"10.1016\/j.berh.2021.101719_bib28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.berh.2021.101719_bib29","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2021.101719_bib30","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2021.101719_bib31","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2021.101719_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","article-title":"The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review","volume":"51","author":"Keenan","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2021.101719_bib33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3899\/jrheum.200460","article-title":"Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR)","volume":"48","author":"Botson","year":"2021","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2021.101719_bib34","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.41731","article-title":"Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101719_bib35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/annrheumdis-2020-eular.3891","article-title":"Leflunomide co-therapy with pegloticase in cintrolled gout","volume":"79","author":"Masri","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101719_bib36","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.semarthrit.2016.09.007","article-title":"Pegloticase failure and a possible solution: immunosuppression to prevent intolerance and inefficacy in patients with gout","volume":"46","author":"Berhanu","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2021.101719_bib37","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.transproceed.2018.03.010","article-title":"A\u00a0case report of immunosuppressant medication\u2012associated polyarticular tophaceous gout successfully treated using the polyethylene glycol\u2012conjugated uricase","volume":"50","author":"Freyne","year":"2018","journal-title":"Enzyme Pegloticase Transplantation Proceedings"},{"issue":"4","key":"10.1016\/j.berh.2021.101719_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.rhu.0000081470.31167.8b","article-title":"Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis","volume":"9","author":"Perez-Ruiz","year":"2003","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.berh.2021.101719_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/CMAMD.S38092","article-title":"Reduction in serum uric acid may Be related to methotrexate efficacy in early rheumatoid arthritis: data from the Canadian early arthritis cohort (CATCH)","volume":"9","author":"Lee","year":"2016","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"10.1016\/j.berh.2021.101719_bib40","doi-asserted-by":"crossref","first-page":"rkaa073","DOI":"10.1093\/rap\/rkaa073","article-title":"Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review","volume":"5","author":"Farquhar","year":"2021","journal-title":"Rheumatology Adv Pract"},{"key":"10.1016\/j.berh.2021.101719_bib41","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","article-title":"Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities","volume":"17","author":"Stamp","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2021.101719_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","article-title":"Allopurinol hypersensitivity: investigating the cause and minimizing the risk","volume":"12","author":"Stamp","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2021.101719_bib43","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome. A proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101719_bib44","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A\u00a0randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101719_bib45","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6mg\/dl: an open label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101719_bib46","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s13075-017-1491-x","article-title":"The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized clinical trial","volume":"19","author":"Stamp","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.berh.2021.101719_bib47","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","article-title":"The British society for rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology"},{"issue":"10156","key":"10.1016\/j.berh.2021.101719_bib48","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.berh.2021.101719_bib49","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semarthrit.2018.02.009","article-title":"Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regression analysis","volume":"48","author":"Stamp","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2021.101719_bib50","doi-asserted-by":"crossref","first-page":"e001628","DOI":"10.1136\/rmdopen-2021-001628","article-title":"12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target","volume":"7","author":"Uhlig","year":"2021","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.berh.2021.101719_bib51","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","article-title":"Adherence and outcomes with urate-lowering therapy: a site-randomized trial","volume":"132","author":"Mikuls","year":"2019","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.berh.2021.101719_bib52","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/acr.23500","article-title":"Development of the American College of rheumatology electronic clinical quality measures for gout","volume":"70","author":"FitzGerald","year":"2018","journal-title":"Arthritis Care Res"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:22:02Z","timestamp":1761499322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694221000619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1521694221000619"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2021.101719","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment advances in gout","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2021.101719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101719"}}